Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tizaspray vs Sirdalud in Acute Low Back Pain
NCT02934061Phase 3Completed
- Sponsor
- MDM Pharma
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Tizaspray in acute low back pain (2 arms), sponsored by MDM Pharma. Primary endpoints: Hand-to-floor distance at Day 1, Low Back Pain Intensity Scale (VAS) at Day 1 and 2 more. Started Oct 2016; status: completed.
02
Drugs
Tizaspray
03
Conditions
acute low back pain
Beyond the preview
Go deeper on NCT02934061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02934061.